Performance of plasma p-tau217 for the detection of amyloid-β positivity in a memory clinic cohort using an electrochemiluminescence immunoassay-Reference-Cited by-同舟云学术

Performance of plasma p-tau217 for the detection of amyloid-β positivity in a memory clinic cohort using an electrochemiluminescence immunoassay

Published:2024-08-19 Issue:1 Volume:16 Page:
ISSN:1758-9193
Container-title:Alzheimer's Research & Therapy
language:en
Short-container-title:Alz Res Therapy

Author:

Dyer Adam H.,Dolphin Helena,O’Connor Antoinette,Morrison Laura,Sedgwick Gavin,Young Conor,Killeen Emily,Gallagher Conal,McFeely Aoife,Connolly Eimear,Davey Naomi,Claffey Paul,Doyle Paddy,Lyons Shane,Gaffney Christine,Ennis Ruth,McHale Cathy,Joseph Jasmine,Knight Graham,Kelly Emmet,O’Farrelly Cliona,Fallon Aoife,O’Dowd Sean,Bourke Nollaig M.,Kennelly Sean P.

Funder

Meath Foundation

Wellcome Trust

Health Research Board

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s13195-024-01555-z.pdf

Reference60 articles.

1. Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol. 2021;20(6):484–96.

2. Dolphin H, Dyer AH, Morrison L, Shenkin SD, Welsh T, Kennelly SP. New horizons in the diagnosis and management of Alzheimer’s disease in older adults. Age Ageing. 2024;53(2):5.

3. Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673–84.

4. Shimohama S, Tezuka T, Takahata K, Bun S, Tabuchi H, Seki M, et al. Impact of Amyloid and Tau PET on changes in diagnosis and patient management. Neurology. 2023;100(3):e264–74.

5. Arslan B, Zetterberg H, Ashton NJ. Blood-based biomarkers in Alzheimer’s disease - moving towards a new era of diagnostics. Clin Chem Lab Med. 2024;62:1063–9.